Streetbeat News

HLVX

HilleVax, Inc.

https://www.hillevax.com

Industry

Biotechnology

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Open

1.99

Mkt cap

98M

Volume

239K

High

1.99

P/E Ratio

-0.64

52-wk high

20.22

Low

1.95

Div yield

N/A

52-wk low

1.55

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Neutral rating on HilleVax (NASDAQ:HLVX) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:14 pm

HilleVax (NASDAQ:HLVX) reported a Q2 2024 GAAP EPS of $(0.83), missing the analyst consensus estimate of $(0.43) by 93.02%. This represents a 12.16% increase in losses compared to the same period last year. The company has $245.0 million in cash, cash equivalents, and marketable securities as of June 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:57 am

HilleVax plans to reduce its workforce by approximately 40%, affecting around 41 employees. This move aims to preserve cash while continuing the development of its HIL-214 and HIL-216 norovirus vaccine candidates and related business activities.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:05 pm

Trading halt status for HLVX was updated at 7:55:00 AM ET. The quotation resumption times and related news are expected to follow.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 11:55 am

HilleVax, Inc. (NASDAQ:HLVX) announced that its Phase 2b NEST-IN1 study of the norovirus vaccine HIL-214 in infants did not meet its primary efficacy endpoint. The study showed a vaccine efficacy of 5%, with no clinical benefit observed across secondary endpoints. HilleVax plans to discontinue further development of HIL-214 in infants but will explore its potential in adults.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 11:35 am

Trading for HLVX was halted at 7:27:18 a.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 11:27 am

Core & Main Inc (NYSE:CNM) shares fell 11.4% after reporting mixed first-quarter financial results, missing earnings expectations but slightly beating sales estimates. Other notable stock movements include significant gains for MicroAlgo Inc (NASDAQ:MLGO) and Sobr Safe Inc (NASDAQ:SOBR), and substantial losses for ENDRA Life Sciences Inc (NASDAQ:NDRA) and Avalon Globocare Corp (NASDAQ:ALBT).

Portfolio Pulse from Avi Kapoor

June 04, 2024 | 4:54 pm

U.S. stocks were mixed on Tuesday, with the Dow Jones index gaining around 20 points. Several stocks saw significant gains, including Saia Inc, Annexon, Core Scientific, and others. Saia Inc reported an 18% increase in LTL shipments per workday in April, leading to a 12.3% rise in its shares. Annexon surged 40% after its Phase 3 trial met its primary endpoint. Core Scientific climbed 29% following the signing of 12-year contracts with CoreWeave. Other notable gainers included Terawulf, Zai Lab, Hillevax, and more.

Portfolio Pulse from Avi Kapoor

June 04, 2024 | 2:09 pm

Shares of Applied DNA Sciences (APDN) fell sharply by 67.5% after announcing a $12 million public offering. Other notable stock movements include Sharps Technology (STSS) climbing 207%, Insmed Incorporated (INSM) jumping 110% on positive Phase 3 study results, and Pineapple Energy (PEGY) gaining 91.5% after a subsidiary signed a significant project. Several other stocks experienced significant gains and losses during Tuesday's mid-day session.

Portfolio Pulse from Avi Kapoor

May 28, 2024 | 5:24 pm

JP Morgan analyst Eric Joseph maintains an Overweight rating on HilleVax (NASDAQ:HLVX) and raises the price target from $21 to $24.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.